Soligenix, Inc (NASDAQ: SNGX) CEO Dr. Chris Schaber talks about their two Phase III trials and upcoming interim analysis

INTERVIEW HIGHLIGHTS: *Two Pivotal Phase III studies for T-cell Lymphoma and Oral mucositis *Enrollment milestone for SGX942 *Upcoming interim analysis for SGX942 in September *Top-line final results for CTCL expected in 1Q 2020 INTERVIEW SUMMARY: […]